We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma.
- Authors
Jun Cao; Yaner Yu; Yangkun Zhou; Qing Ji; Wenkang Qian; Dongdong Jia; Gu Jin; Yajun Qi; Xin Li; Ningning Li; Tao Li; Meiyu Fang; Hongchuan Jin
- Abstract
Introduction: Sinonasal mucosal melanoma (SNMM) originates from melanocytes. Currently, the main treatment methods, including surgery, radiotherapy and chemotherapy, have little effect on the recurrence and metastasis of SNMM. However, targeted therapy may be a breakthrough in treating SNMM. Methods: A SNMM patient with ROS1 fusion received 250mg Crizotinib capsule (2 times a day, 1 tablet each time) therapy. Results: The patient achieved partial remission after 4 months of treatment and complete remission after 8 months of treatment. Conclusion: Our findings suggest that crizotinib can be an option to improve overall survival and quality of life of patients with metastatic ROS1-fusion SNMM. We believe that our report will provide insights for the application of crizotini in the treatment of melanoma.
- Subjects
PARANASAL sinuses; CRIZOTINIB; MELANOMA; CANCER relapse; OVERALL survival
- Publication
Frontiers in Oncology, 2022, Vol 12, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2022.942258